Slide 1: FY2026-1Q Financial Results Summary
FY2026-1Q Financial Results Summary May 2026
Slide 2: Major Business Highlights for FY2026-1Q
Major Business Highlights for FY2026-1Q 【 HGF Gene Therapy Product 】：Advancing BLA Preparation in the US US：Clinical trials have been completed, and preparation for the Biologics License Application (BLA) is underway in consultation with the FDA. Type B Clinical Meeting with the FDA was conducted. →
Slide 3: Major Business Highlights for FY2026-1Q
Major Business Highlights for FY2026-1Q 【ACRL】：Order Intake for Expanded Newborn Screening Remains Stable ・Expanded Newborn Screening The number of target diseases has expanded from 9 to 14, and order intake remains stable, operating at near full capacity. ・Establishment of a Comprehensive Testing F
Slide 4: Performance for FY2026-1Q
Performance for FY2026-1Q Business revenue increased, while operating expenses rose due to HGF application preparation costs （Unit：Million Yen） Revenue（YoY+20.4％） FY2025-1Q FY2026-1Q Change ・Expanded newborn screening testing at ACRL totaled 124 millionYen (YoY+9..7%) ・Zokinvy sales amounted to 78 m
Slide 5: Consolidated Balance Sheet Highlights
Consolidated Balance Sheet Highlights （Unit：Million Yen） Curent Assets Dec-2025 March-2026 Change ・414 millionYen was raised through the issuance of the 46th series of stock acquisition rights. ・Current assets decreased by 1,018 millionYen Current Assets 4,386 3,367 -1,018 due to expenditures such a
Slide 6: Genetic Innovation for All
Genetic Innovation for All https://www.anges.co.jp/en